Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dishman Carbogen Amcis Ltd. ( (IN:DCAL) ) has provided an announcement.
Dishman Carbogen Amcis reported consolidated net revenue of Rs 7,198 million for the third quarter of FY26, a 5.5% year-on-year increase driven mainly by higher CDMO revenue, while Q3 EBITDA declined to Rs 1,131 million and EBITDA margin contracted to 15.7% from 20.5%. For the first nine months of FY26, net revenue rose 4.3% to Rs 20,805 million, supported by strong growth in cholesterol and Vitamin D analogue sales and higher CDMO development revenue, lifting EBITDA to Rs 4,027 million and expanding the nine-month EBITDA margin to 19.4%, despite a softer performance in the Marketable Molecules segment in the latest quarter due to lower quats revenue.
More about Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Ltd. is a fully integrated contract development and manufacturing organisation (CDMO) serving innovator pharmaceutical companies, with capabilities spanning process research and development through late-stage clinical and commercial manufacturing and supply of active pharmaceutical ingredients (APIs). The company operates across CDMO services and a Marketable Molecules segment, including cholesterol and Vitamin D analogues, with a focus on global pharma markets.
Average Trading Volume: 14,332
Technical Sentiment Signal: Buy
Current Market Cap: 33.77B INR
Find detailed analytics on DCAL stock on TipRanks’ Stock Analysis page.